Romy 250 mcg Injection belongs to a thrombopoietin receptor agonists or type of meditation which increases the Number of Platelets in order to lessen the chances of bleeding in patients with Immune Thrombocytopenia(ITP) Idiopathic Thrombocytopenia Purpura or in conditions associated with Bleeding or bruising due to an abnormally low level of platelets in the blood. It induces the cells in the bone marrow to increase the formation of Platelets. Romy 250 mcg Injection should not be used in the patient with Myelodysplastic Syndrome, a condition in which bone marrow is unable to produce healthy cells. Generally, it is given after other medications fail to produce enough results.
Romy 250 mcg Injection is Protein-based Therapy responsible for Hematopoietic growth that results in the management og ITP.
Romy 250 mcg Injection comes as a Powder form that should be mixed with liquid to be injected Subcutaneous route. The initial dose is 1mcg/kg but not more than 10mcg/kg/week. It should be administered by a Professional Health worker or Specialist or trained medical staff only, and one should avoid Self-administration. Your doctor may put you on Romy 250 mcg Injection with a low dose or may adjust the dose compatible with your body and its response. It is not necessary that it works for everyone; some patients might not get a response to this drug; in such case, your doctor may discontinue this treatment option. Romy 250 mcg Injection is always advisable to take it under the supervision of your Health care professional only. Tell your doctor if you have ever had Leukemia, Blood clot problem, Spleen removal or Liver disease as it is strictly Contraindicated in such patients.
Romy 250 mcg Injection Thrmbopoietin receptor agonist also called Platelet Stimulating agent. It helps increase Platelets count by inducing Bone marrow cells to produce more and more platelets. It activates the TPO receptor on megakaryocyte precursors by binding with it, promoting cell proliferation and viability, resulting in increased platelet production. This reduces the bleeding events in patients with Thrombocytopenia.